Navigation Links
Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets
Date:2/24/2009

ions that retain their drug-binding characteristics. The Company can then apply contemporary drug discovery approaches, such as crystallisation and structure-based design, biophysical analysis of ligand interactions, and fragment screening to stabilised GPCRs. This unique approach is expected to radically improve the chances of finding drugs to previously intractable targets and enable the development of safer and more selective therapeutic agents.

Heptares was founded in 2007 as a spin-out from the prestigious MRC Laboratory of Molecular Biology (Cambridge, UK) based on world-class pioneering research and expertise in GPCRs. In 2008, the StaR technology was used successfully to elucidate the three-dimensional atomic resolution structure of the beta-1 adrenergic receptor, which is the site of action of beta blockers.

Heptares' CEO, Dr Malcolm Weir, said: "We are very pleased to have completed this significant fundraising in the current economic environment. We are delighted to have attracted such a truly international group of blue-chip investors and see this as a real endorsement of the quality and commercial potential of our StaR technology. We now have a very good opportunity to implement our strategy for generating new drug candidates to highly validated but previously challenging GPCRs."

Dr Michael Steinmetz, Managing Partner at Clarus Ventures, said: "Heptares has made impressive progress in developing its unique StaR technology since its inception in 2007. Its platform has the potential to make important GPCR drug targets accessible to drug discovery techniques previously not applicable to this class of proteins. The commercial opportunity arising from developing new first/best-in-class drugs to GPCRs is clear, particularly with pharmaceutical company pipelines under pressure. We are pleased and excited to participate in this funding round with MVM and Novartis Option Fund, and are committed t
'/>"/>

SOURCE Heptares Therapeutics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Northwest Biotherapeutics Secures $700,000 Equity Financing
3. Intelligroup Secures Multi-Million Dollar COSMOS Implementation with Almac Clinical Services
4. TaiGen Biotechnology Secures 37 Million USD in Series C Round Financing
5. Pharmacyclics Secures $5.0 Million in Debt Financing
6. EcoSphere(R) Biolatex(TM) Secures Funding from Granholm and Invest Michigan!
7. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
8. Queens secures £25M for UKs cyber safety
9. Queens secures £25m for UKs cyber-safety
10. Northwest Secures US$1.65 Million Debt Financing
11. NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Clara, California (PRWEB) March 03, 2015 ... development service company, has launched a new Life Science ... reagents for preclinical research. , The first products ... antibody isotype controls, and soon to be released in ... company will continue to expand their life science portfolio ...
(Date:3/3/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... Expert Opinion on Biological Therapy , Dr. ... Zhang , at the Henry Ford Hospital in ... 4 (TB4) has the capacity to promote CNS and ... post-injury, leading to neurological recovery in each case.  They ...
(Date:3/3/2015)... 2015 Becht Engineering Co., Inc., ... has acquired The CECON Group, Inc., located in ... not announced. , Becht Engineering (http://www.becht.com ) ... including oil and gas production, refining, petrochemical, chemical, ... power sectors. The company has twelve offices in ...
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. , ... viral vectors, nonviral vectors and cell therapy with ... method of drug delivery and various routes of ...
Breaking Biology Technology:Crown Bioscience Launches Life Science Product Catalog 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3
... June 15 Finesse Solutions, LLC, San Jose, CA, a ... its move from a facility in Santa Clara, CA, to ... new address is 71 Daggett Drive, San Jose, CA, 95134. ... from Irvine, CA to Silicon Valley. , , The ...
... MedPredict Market Research, a global provider of pharmaceutical competitive ... entitled "Thought Leader Insight & Analysis: Alzheimer,s Disease," designed ... companies with a stake in the market for diagnostics ... http://www.medpredict.com/website/home.aspx ). , , MedPredict ...
... , - Improving Research ... today announced a new partnership agreement with NextBio,provider of ... discover, and share knowledge locked within public and proprietary,data ... of NextBio,s unique set of ontology-based semantic tools and ...
Cached Biology Technology:New MedPredict Report Reveals Top Alzheimer's Experts' Insights on Diagnostics and Treatments in Development Pipeline 2Elsevier and NextBio Sign Partnership to Enrich ScienceDirect Content, Accelerating Life Sciences, Health Sciences and Chemistry Research 2Elsevier and NextBio Sign Partnership to Enrich ScienceDirect Content, Accelerating Life Sciences, Health Sciences and Chemistry Research 3Elsevier and NextBio Sign Partnership to Enrich ScienceDirect Content, Accelerating Life Sciences, Health Sciences and Chemistry Research 4
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... PARK, N.C. , Feb. 5, 2015  Marken ... specialist logistics company and has launched a new marketing ... Clinical Logistics Organization (CLO).  The new campaign focuses on ... on patient, protocol and shipments. The first ... , aligns Marken,s priorities with its client,s priorities. ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... Mich---University of Michigan researchers have determined that most types ... evidence that the deadliest form of skin cancer does ... model. In addition, the researchers found that melanoma ... genes on and off, making the malignant cells a ...
... WASHINGTON Though the massive glaciers of the greater ... steps now to help the region,s communities prepare for ... their lives, according to a new report. Programs that ... needed to adequately address these impacts, the report states. ...
... Ill. University of Illinois researchers are using a new ... in biology the relationship between cell mass and growth ... and bioengineering professor Rashid Bashir, published its results in the ... Academy of Sciences . "It,s merging micro-scale engineering and ...
Cached Biology News:More evidence that melanoma does not conform to the cancer stem cell model 2More evidence that melanoma does not conform to the cancer stem cell model 3Time to prepare for climate change 2Time to prepare for climate change 3Time to prepare for climate change 4Time to prepare for climate change 5Microsensors offer first look at whether cell mass affects growth rate 2
streptavidin, Alexa Fluor® 750–allophycocyanin conjugate (Alexa Fluor® 750–allophycocyanin streptavidin) *1 mg/mL*...
AedestaTM Animal Organ/Tissue Perfusion Soln....
Reusble. Uses in conjunction with the Apoptotic Cell Isolation Kit....
EGTA, 10 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: